Christopher Yea

944 total citations
28 papers, 692 citations indexed

About

Christopher Yea is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Christopher Yea has authored 28 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Genetics and 7 papers in Immunology. Recurrent topics in Christopher Yea's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers), Biochemical and Molecular Research (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers). Christopher Yea is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers), Biochemical and Molecular Research (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers). Christopher Yea collaborates with scholars based in United Kingdom, United States and France. Christopher Yea's co-authors include P.A. Robson, Robert Westwood, Richard A. Williamson, Elizabeth Kuo, E. Ruuth, Jean‐Michel Bruneau, Andrew R. Cross, Catherine Sautès‐Fridman, Owen Jones and P. Hambleton and has published in prestigious journals such as Journal of Biological Chemistry, Biochemical Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Christopher Yea

27 papers receiving 652 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Yea United Kingdom	13	316	113	103	83	68	28	692
P.A. Robson France	12	300 0.9×	63 0.6×	77 0.7×	45 0.5×	61 0.9×	14	652
David P. Hesson United States	12	455 1.4×	129 1.1×	354 3.4×	53 0.6×	40 0.6×	20	1.1k
Junying Zheng United States	17	330 1.0×	96 0.8×	111 1.1×	28 0.3×	36 0.5×	26	823
Joleen T. White United States	16	709 2.2×	144 1.3×	29 0.3×	59 0.7×	41 0.6×	29	1.1k
Janine Reunert Germany	20	507 1.6×	105 0.9×	165 1.6×	47 0.6×	46 0.7×	45	880
Elisabetta Grillo Italy	20	450 1.4×	103 0.9×	41 0.4×	30 0.4×	37 0.5×	55	1.0k
Anne N. Shemon Australia	14	266 0.8×	206 1.8×	27 0.3×	42 0.5×	49 0.7×	16	1.0k
Masayuki Haramura Japan	11	191 0.6×	66 0.6×	34 0.3×	29 0.3×	225 3.3×	44	620
Christine Huppertz Switzerland	16	481 1.5×	154 1.4×	90 0.9×	17 0.2×	67 1.0×	20	910
J Jaeken Belgium	11	421 1.3×	35 0.3×	73 0.7×	24 0.3×	41 0.6×	19	760

Countries citing papers authored by Christopher Yea

Since Specialization

Citations

This map shows the geographic impact of Christopher Yea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Yea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Yea more than expected).

Fields of papers citing papers by Christopher Yea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Yea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Yea. The network helps show where Christopher Yea may publish in the future.

Co-authorship network of co-authors of Christopher Yea

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Yea. A scholar is included among the top collaborators of Christopher Yea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Yea. Christopher Yea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Longhurst, Hilary, Mauro Cancian, Vesna Grivcheva‐Panovska, et al.. (2024). Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review. Clinical Reviews in Allergy & Immunology. 67(1-3). 83–95. 5 indexed citations

Riedl, Marc A., Emel Aygören‐Pürsün, William R. Lumry, et al.. (2024). Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results of the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial. Journal of Allergy and Clinical Immunology. 153(2). AB375–AB375.

Cohn, Danny M., Emel Aygören‐Pürsün, Jonathan A. Bernstein, et al.. (2023). Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. Clinical and Translational Allergy. 13(9). e12288–e12288. 8 indexed citations

Smith, M. Hamblin, et al.. (2023). A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers. Journal of Allergy and Clinical Immunology. 151(2). AB140–AB140. 1 indexed citations

Murugesan, Nivetha, Lily Li, Gian Marco De Donatis, et al.. (2022). Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema. Clinical & Experimental Allergy. 52(9). 1059–1070. 15 indexed citations

Maetzel, Andreas, Michael D. Smith, Gian Marco De Donatis, et al.. (2022). KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. Journal of Allergy and Clinical Immunology. 149(6). 2034–2042. 12 indexed citations

Bernstein, Jonine L., Christopher Yea, Andreas Maetzel, et al.. (2021). A022 ON-DEMAND ORAL TREATMENT WITH KVD900 FOR HAE ATTACKS ACHIEVES RAPID EXPOSURE AND IMPROVES PATIENT OUTCOMES. Annals of Allergy Asthma & Immunology. 127(5). S4–S5. 1 indexed citations

Donatis, Gian Marco De, Nivetha Murugesan, Lily Li, et al.. (2019). KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study. Journal of Allergy and Clinical Immunology. 143(2). AB39–AB39. 4 indexed citations

Yea, Christopher, et al.. (2013). The Antidiuretic Effect of Fedovapagon can be Effectively Controlled by Dose. Neurourology and Urodynamics. 2 indexed citations

10.

Golor, Georg, et al.. (2013). Antidiuretic Effect of Fedovapagon in Older Males with Benign Prostatic Hyperplasia and Nocturia. Neurourology and Urodynamics. 2 indexed citations

11.

Yea, Christopher, Doreen M. Ashworth, James W. Barnett, et al.. (2008). New Benzylureas as a Novel Series of Potent, Nonpeptidic Vasopressin V2 Receptor Agonists. Journal of Medicinal Chemistry. 51(24). 8124–8134. 31 indexed citations

12.

Princivalle, M, et al.. (2006). Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist. Journal of Pharmacology and Experimental Therapeutics. 320(3). 1113–1118. 44 indexed citations

13.

Haigh, R., P.A. Robson, André Tartar, et al.. (2004). Non-peptide oxytocin agonists. Bioorganic & Medicinal Chemistry Letters. 14(17). 4585–4589. 51 indexed citations

14.

Curnock, Adam P., Tom Thomson, Robert Westwood, et al.. (2001). Inhibition of stimulated Jurkat cell adenosine 3′,5′-cyclic monophosphate synthesis by the immunomodulatory compound HR32577Abbreviations: PGE2, prostaglandin E2; FKN, forskolin; CTX, cholera toxin; cAMP, adenosine 3′,5′-cyclic monophosphate; IBMX, 3-isobutyl-1-methylxanthine; NCA, niclosamide; FCCP, carbonyl cyanide p-trifluoromethoxyphenyl hydrazone; DHO-DH, dihydroorotate dehydrogenase; IL-2, interleukin-2; and HBSS, Hanks’ balanced salt solution.. Biochemical Pharmacology. 61(2). 227–235. 8 indexed citations

15.

Fassy, Florence, et al.. (1998). Enzymatic activity of two caspases related to interleukin‐1β‐converting enzyme. European Journal of Biochemistry. 253(1). 76–83. 14 indexed citations

16.

Bruneau, Jean‐Michel, Christopher Yea, P.A. Robson, et al.. (1998). Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochemical Journal. 336(2). 299–303. 113 indexed citations

17.

Curnock, Adam P., P.A. Robson, Christopher Yea, et al.. (1997). Potencies of Leflunomide and HR325 as Inhibitors of Prostaglandin Endoperoxide H Synthase-1 and -2: Comparison with Nonsteroidal Anti-Inflammatory Drugs. Journal of Pharmacology and Experimental Therapeutics. 282(1). 339–347. 14 indexed citations

18.

Williamson, Richard A., Christopher Yea, P.A. Robson, et al.. (1995). Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound. Journal of Biological Chemistry. 270(38). 22467–22472. 173 indexed citations

19.

Yea, Christopher, et al.. (1991). Inhibition of myeloperoxidase by synovial fluid and serum.. Annals of the Rheumatic Diseases. 50(6). 383–388. 4 indexed citations

20.

Yea, Christopher, Andrew R. Cross, & Owen Jones. (1990). Purification and some properties of the 45 kDa diphenylene iodonium-binding flavoprotein of neutrophil NADPH oxidase. Biochemical Journal. 265(1). 95–100. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact